A little perspective please.There's a difference between building a company in its first year and the results of operations of that company two or three years in. Up until Jan 1, 2020 Zenabis has been building out it's cannabis growing facilities, hiring staff, working with consultants, working with banks and investors for financing, putting together a plan, sizing up competitors, scouting the globe for the right opportunity to partner with someone, to open up new channels to sell product through. As of Jan 1, 2020 they are ready to go. Let's give them one quarter to see what they can do. They made C$74 million dollars in revenue last year. That was an 800% increase from the previous year. From here on out this company has no excuses, they must produce increased revenue, increased margins and an expectation of profitability by years end. If they can do that, then their stock price will go up accordingly. Anyone who bought Zenabis at a relatively high price needs to take responsibility of not knowing exactly what they were doing. Companies don't make money at first, they run up hundreds of millions of dollars in debt, continuously sell warrants and all grades of shares to raise money to build the company. All this doesn't boost the stock price, it lowers it. Zenabis is not Amazon. Zenabis has lots of competitors in the exact same space. Zenabis didn't go buying all sorts of companies and then having to write down a billion dollars like Aurora. Organagram can't increase revenue from quarter to quarter, Sundial is a mess, Tilray reports $167 mil in revenue for 2019 and a loss of 321 mil plus, due to the money they had to spend while overextending themselves globally. Cronos's revenue is $25 mil for all of last year, their stock price is over $6.00 their price to sales is 91.23 but they have one point some odd billion in cash on hand. Zenabis price to sales is .41 Canopy is in the best shape, $2.3 billion in cash, $124 mil revenue in the last quarter, $92 mil loss last quarter, 76,700 Canadian medical patients and a gross margin of 34% which is not that great but by far Canopy is the industry leader imo. with Aphria coming in second. Now let's see if Aphria can streamline their operations reduce costs and get that margin and profit up next quarter. My larger point here is that Zenabis is as well run a company if not better than any and all the industry leaders. They are just one year behind them all operationally. There's a reason why at this early stage, many serious players in the Canadian cannabis industry have been looking to Zenabis to supply them with product. Pax, Tilray, Starseed, Tantulus labs. These companies evidently trust Zenabis to be a trusted partner in delivering on what they agreed on. Zenabis seems to be building a reputation for quality and dependability or these companies would not be doing business with them. Just my take. The Bevo culture has rubbed off on Zenabis. Honest dealings, dependable service and top quality product. Give it time, Zenabis will deliver, they already have. Buy all you can at .06 cents, you won't regret it in the months and years ahead. I could be wrong but I don't think I am. At .06 per share, Zenabis is a lottery ticket.